A federal judge in California is set to decide whether to dismiss 21 products liability lawsuits filed against Medtronic Inc. alleging off-label use of its Infuse bone-graft device.
Infuse, a bioengineered bone-growth protein used in spinal surgeries, has spawned at least 750 lawsuits and potentially 2,600 additional unfiled claims against Medtronic, according to the company’s June 20 annual report.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
